Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2006

View Archived Issues

Nalmefene shows promise in treating pathological gambling / News in Context

NXY-059 appears to reduce disability in ischemic stroke patients

LRH-1 activation: Potential efficacy as a treatment for atherosclerosis

New localized radiotherapeutic for prostate cancer

Capsaicin patch reduces pain in HIV-associated distal sensory polyneuropathy

GCPII inhibitor targeted for neuroprotection and prostate cancer

Neurochem completes rolling NDA for Fibrillex in AA amyloidosis

Phase I study of lemuteporfin in BPH fails to meet primary efficacy objective

Santen updates status of ophthalmic programs

ProMetic BioSciences cleared for Canadian phase Ib/II study of PBI-1402

Ranbaxy and CIH establish joint venture for antiretrovirals in South Africa

Eltrombopag begins phase III trials for ITP

Avant's typhoid fever vaccine Ty-800 studied in new phase I/II trial

BioXell and Lay Line Genomics sign agreement for MNAC13

European COMP recommends orphan drug designation for 1D09C3

Orthokine approved in E.U.

Glenmark discovers new drug targeting obesity

Retapamulin NDA under FDA review

Pfizer looks to value drivers to grow business

Prophylactic and therapeutic efficacy of targeting TLR9 for HSV-2

Recent Incyte patent describes new therapeutic agents for HIV infection

New agents for endocrine-related disorders imparted in recent patent literature

Orphan drug designation for TRX-4 in type 1 diabetes

Phase Ib trial investigates AP-23573 plus doxorubicin for cancer

MB-07803 studied in phase I for type 2 diabetes

New therapeutic agents described for cardiovascular disorders

Japanese phase II trial for gaboxadol

Ambrisentan use in PAH patients who discontinue other ERA therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...